[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20211670T1 - Derivat difenilmetana u kristalnom obliku - Google Patents

Derivat difenilmetana u kristalnom obliku Download PDF

Info

Publication number
HRP20211670T1
HRP20211670T1 HRP20211670TT HRP20211670T HRP20211670T1 HR P20211670 T1 HRP20211670 T1 HR P20211670T1 HR P20211670T T HRP20211670T T HR P20211670TT HR P20211670 T HRP20211670 T HR P20211670T HR P20211670 T1 HRP20211670 T1 HR P20211670T1
Authority
HR
Croatia
Prior art keywords
crystalline form
xrd
irradiation
spectrum
light source
Prior art date
Application number
HRP20211670TT
Other languages
English (en)
Inventor
Hee-Kyoon Yoon
Se-Hwan Park
Ji-Sung Yoon
Soongyu Choi
Hee Jeong Seo
Eun-Jung Park
Younggyu Kong
Kwang-Seop Song
Min Ju Kim
So Ok PARK
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co., Ltd., Green Cross Corporation filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of HRP20211670T1 publication Critical patent/HRP20211670T1/hr
Publication of HRP20211670T8 publication Critical patent/HRP20211670T8/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (1)

1. Kristalni oblik spoja sljedeće Formule c28. [image] pri čemu kristalni oblik ima spektar difrakcije rendgenskih zraka (XRD) koji uključuje vrhove pod kutovima difrakcije (2θ) od 6.2°±0.2°, 7.2°±0.2°, 8.8°±0.2°, 17.6°±0.2°, 19.0°±0.2°, 22.5°±0.2°, i 25.1°±0.2° u slučaju zračenja pomoću Cu-Kα izvora svjetlosti; ili pri čemu kristalni oblik ima spektar difrakcije rendgenskih zraka (XRD) koji uključuje vrhove pod kutovima difrakcije (2θ) od 7.0°±0.2°, 14.9°±0.2°, 17.7°±0.2°, 18.8°±0.2°, 20.6°±0.2°, 21.8°±0.2°, i 23.5°±0.2° u slučaju zračenja pomoću Cu-Kα izvora svjetlosti; ili pri čemu kristalni oblik ima spektar difrakcije rendgenskih zraka (XRD) koji uključuje vrhove pod kutovima difrakcije (2θ) od 5.6°±0.2°, 7.3°±0.2°, 15.7°±0.2°, 17.2°±0.2°, 18.9°±0.2°, 21.2°±0.2°, i 21.9°±0.2° u slučaju zračenja pomoću Cu-Kα izvora svjetlosti; ili pri čemu kristalni oblik ima spektar difrakcije rendgenskih zraka (XRD) koji uključuje vrhove pod kutovima difrakcije (2θ) od 5.5°±0.2°, 7.2°±0.2°, 15.3°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.9°±0.2°, i 21.1°±0.2° u slučaju zračenja pomoću Cu-Kα izvora svjetlosti.
HRP20211670TT 2016-06-17 2017-06-15 Derivat difenilmetana u kristalnom obliku HRP20211670T8 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
EP20152959.1A EP3663292B1 (en) 2016-06-17 2017-06-15 Diphenylmethane derivative in crystalline form

Publications (2)

Publication Number Publication Date
HRP20211670T1 true HRP20211670T1 (hr) 2022-02-18
HRP20211670T8 HRP20211670T8 (hr) 2022-03-18

Family

ID=60664449

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211670TT HRP20211670T8 (hr) 2016-06-17 2017-06-15 Derivat difenilmetana u kristalnom obliku

Country Status (30)

Country Link
US (2) US10640496B2 (hr)
EP (2) EP3473621B1 (hr)
JP (4) JP6763978B2 (hr)
KR (2) KR102233229B1 (hr)
CN (2) CN113651803B (hr)
AU (1) AU2017285813B2 (hr)
BR (1) BR112018076243A2 (hr)
CA (2) CA3026756C (hr)
CL (1) CL2018003645A1 (hr)
CO (1) CO2018014018A2 (hr)
DK (2) DK3663292T3 (hr)
DO (1) DOP2018000287A (hr)
EC (1) ECSP19000185A (hr)
ES (2) ES2898336T3 (hr)
HR (1) HRP20211670T8 (hr)
HU (1) HUE056428T2 (hr)
MA (2) MA44545B2 (hr)
MX (2) MX2021008988A (hr)
MY (1) MY203941A (hr)
NZ (1) NZ749398A (hr)
PE (2) PE20240590A1 (hr)
PH (1) PH12018550206A1 (hr)
PL (2) PL3473621T3 (hr)
PT (2) PT3473621T (hr)
RS (1) RS62550B1 (hr)
SA (2) SA518400666B1 (hr)
SG (2) SG11201811154QA (hr)
SI (1) SI3663292T1 (hr)
TN (1) TN2018000437A1 (hr)
WO (1) WO2017217792A1 (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
KR102307475B1 (ko) * 2018-08-13 2021-09-30 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체의 제조
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
AU2021225706B2 (en) * 2020-02-27 2024-06-13 Daewoong Pharmaceutical Co., Ltd. Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
CA3191689A1 (en) 2020-09-10 2022-03-17 Zhining HUANG Synthesis method for preparing sglt inhibitor intermediate
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
KR20240044190A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
WO2024136385A1 (ko) 2022-12-21 2024-06-27 주식회사 대웅테라퓨틱스 이나보글리플로진을 포함하는 점안제 형태의 약학 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
EA010299B1 (ru) * 2003-08-01 2008-08-29 Мицубиси Танабе Фарма Корпорейшн Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортёра
NZ582536A (en) 2007-07-26 2012-01-12 Lexicon Pharmaceuticals Inc Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
TW201018695A (en) 2008-07-30 2010-05-16 Ferrer Int 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
KR101576589B1 (ko) 2011-06-01 2015-12-10 주식회사 녹십자 Sglt2 억제제로서의 신규한 다이페닐메탄 유도체
US9340521B2 (en) 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MA50774B1 (fr) 2022-02-28
EP3473621A1 (en) 2019-04-24
KR20210036892A (ko) 2021-04-05
MX2021008988A (es) 2022-05-05
CN113651803B (zh) 2022-10-28
JP2019521985A (ja) 2019-08-08
SI3663292T1 (sl) 2022-01-31
MA50774A1 (fr) 2021-03-31
RU2021129636A (ru) 2021-11-22
JP2020117528A (ja) 2020-08-06
SA518400666B1 (ar) 2021-11-30
CA3081033A1 (en) 2017-12-21
MX2018015647A (es) 2019-04-11
SG11201811154QA (en) 2019-01-30
CL2018003645A1 (es) 2019-03-22
NZ749398A (en) 2020-01-31
EP3663292B1 (en) 2021-09-01
HRP20211670T8 (hr) 2022-03-18
KR102233229B1 (ko) 2021-03-29
RS62550B1 (sr) 2021-12-31
AU2017285813B2 (en) 2020-02-06
MA44545A1 (fr) 2019-10-31
JP7352509B2 (ja) 2023-09-28
CA3081033C (en) 2022-04-12
PT3663292T (pt) 2021-11-08
US20190382390A1 (en) 2019-12-19
US10889574B2 (en) 2021-01-12
AU2017285813A1 (en) 2019-01-17
PE20190467A1 (es) 2019-04-04
MY203941A (en) 2024-07-25
EP3663292A1 (en) 2020-06-10
EP3473621A4 (en) 2020-03-11
HUE056428T2 (hu) 2022-02-28
CN109311861A (zh) 2019-02-05
PL3473621T3 (pl) 2022-01-10
JP6763978B2 (ja) 2020-09-30
CA3026756C (en) 2021-03-02
ECSP19000185A (es) 2019-01-31
DK3663292T3 (da) 2021-10-25
MA44545B2 (fr) 2020-11-30
EP3473621B1 (en) 2021-08-04
CA3026756A1 (en) 2017-12-21
RU2019101056A3 (hr) 2020-07-17
TN2018000437A1 (en) 2020-06-15
CN109311861B (zh) 2021-08-24
KR102379584B1 (ko) 2022-03-29
KR20170142904A (ko) 2017-12-28
JP2023145481A (ja) 2023-10-11
PT3473621T (pt) 2021-10-04
DK3473621T3 (da) 2021-09-06
MA44545B1 (fr) 2020-05-29
US10640496B2 (en) 2020-05-05
RU2019101056A (ru) 2020-07-17
SA521422474B1 (ar) 2023-11-02
JP2021152054A (ja) 2021-09-30
CN113651803A (zh) 2021-11-16
PE20240590A1 (es) 2024-03-21
CO2018014018A2 (es) 2019-03-08
WO2017217792A1 (ko) 2017-12-21
BR112018076243A2 (pt) 2019-03-26
ES2898336T3 (es) 2022-03-07
US20190169174A1 (en) 2019-06-06
SG10201911782RA (en) 2020-02-27
ES2891825T3 (es) 2022-01-31
PH12018550206A1 (en) 2019-09-30
PL3663292T3 (pl) 2022-01-17
DOP2018000287A (es) 2019-03-31

Similar Documents

Publication Publication Date Title
HRP20211670T1 (hr) Derivat difenilmetana u kristalnom obliku
HRP20210748T1 (hr) Postupak priprave spojeva s aktivnošću inhibitora hiv integraze
PE20141061A1 (es) Compuesto inhibidor de la senalizacion de la trayectoria notch
WO2014136282A8 (en) Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
WO2017100726A8 (en) Methods for treating huntington's disease
JP2019510768A5 (hr)
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
EP3533794A3 (de) Materialien für elektronische vorrichtungen
UY31419A1 (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen
RS52375B (en) STABLE CRYSTALS OF 4-OXOCHINOLINE COMPOUND
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
FI3977993T3 (fi) 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä
AR074507A1 (es) Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra.
AR103444A1 (es) Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
MY189352A (en) Crystals of Azabicyclic Compound
WO2018151479A3 (ko) 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2015000431A9 (zh) 替唑尼特氨基甲酸酯及其在药学中的应用
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
WO2018004315A3 (ko) 화합물 및 이를 포함하는 유기 전자 소자
WO2015017378A3 (en) Novel copper-cysteamine and methods of use
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
JP2015506941A5 (hr)
MX2023004668A (es) Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.
EA202092393A1 (ru) Кристаллическое соединение оксазола
CY1121811T1 (el) Κρυσταλλικες μορφες s-ακετυλ γλουταθειονης, παρασκευη αυτων και χρησεις σε φαρμακευτικα και τροφιμοφαρμακευτικα σκευασματα